CClinicalTrials.gg
Status unknownNCT04872881Updated May 5, 2021

Comparison of Effectiveness of Different Airway Management Methods During Percutaneous Tracheostomy

A Phase 4 interventional study of Endotracheal Tube Insertion and Laryngeal Mask Insertion in Intubation, Intratracheal, Tracheostomy and Laryngeal Masks, sponsored by Bozyaka Training and Research Hospital. Status unknown. Open to participants aged 18 Years to 95 Years. Per ClinicalTrials.gov, last updated 2021-05-05.

Sponsored by Bozyaka Training and Research Hospital · Phase 4, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Apr 2021), so the status shown — last known as Not yet recruiting — may be out of date.
Phase
Phase 4
Study type
Interventional
Enrollment
52
Allocation
Randomized
Ages
18 Years to 95 Years
Sex
All
01

Study summary

Tracheostomy is a vital procedure in the ICU to maintain the airway and prevent complications that may occur due to intubation. It helps reduce the dead space volume, airway resistance and provides comfort to the patients during the weaning from mechanical ventilation. Two methods are widely used in Percutaneous Dilatational Tracheostomy (PDT): The multiple dilation method (Ciaglia) and the Griggs method.Griggs method will be used in the study.

The Griggs Method: A 10-15 millimeter skin incision is made between the level of the second-third tracheal rings. The location of the needle is confirmed by entering the trachea with an injector filled with 2-3 mL saline from the midline and aspirating air. A J-tipped guidewire is advanced through the needle and the needle is removed. A special forceps with a channel at the tip, through which the guidewire can pass is used in this method. The forceps advanced through the guidewire and then subcutaneous tissues and trachea are dilated in one or two steps. When the stoma is large enough to insert the cannula, it is placed in the trachea and fixed.

Patients who will undergo tracheostomy in the ICU will be included in the study and randomly assigned into two groups. Two different methods, endotracheal tube (ET) or laryngeal mask (LMA), will be used during the tracheostomy for airway management. In both methods, fiberoptic bronchoscopy will assist the procedure.

Researchers aim to compare the two airway management methods in terms of complications, procedure time, and the number of staff needed.

Read the detailed description

Protection of the airway during percutaneous tracheostomy can be achieved with an endotracheal tube (ETT) or laryngeal mask (LMA).Researchers aimed to compare the use of ETT and LMA in this prospective, randomized study.

Multiple blood gas analyses will be performed during the procedure. Airway failure rates, total procedure time, the occurrence of gastric distension and regurgitation, number of staff needed, complications (Hypercarbia, hypoxia, etc.), and hemodynamic parameters (Non-invasive blood pressure, pulse oximeter, electrocardiogram) will be compared.

Patients will be divided into two groups with simple randomization. A-priori study with 14 patients suggested 52 patients are needed for statistical significance (G*Power 3.1 software was used). Patients will be reviewed for suitability for procedure as stated in the inclusion criteria. Patients and/or relatives will be informed about the study and informed consent will be obtained. Invasive arterial blood pressure monitoring of the patients will be available. Before the procedure, the patients' fasting period for 6 hours will be completed and the nasogastric catheter will be removed. Arterial blood gas sample will be checked before the procedure begins. By placing a transverse elevation under the shoulders, the patients' neck will be extended as appropriate. Patients will be positioned after induction with 2 mg/kg propofol, 0.6 mg/kg rocuronium, and 1 mcg/kg fentanyl IV, and positioning time will be recorded. Propofol infusion at the dose of 6 mg/kg/hour will be started. Electrocautery will be available. Patients will be mechanically ventilated with a controlled mode (CMV) with 7ml/kg tidal volume, 15/min frequency, and 5 cmH2O PEEP. Preoxygenation will be made with 100% FiO2 for 5 minutes.

ETT Group: ETT will be repositioned with direct laryngoscopy (ETT cuff will be inflated just above the vocal cords). "The Reposition Time" will start with the cuff deflation and end with successful ventilation after repositioning. If the ETT can not be repositioned within 5 minutes, it will be considered as a "Failed Airway" and tracheostomy will be continued with the usual method (ETT cuff will be inflated under the vocal cords).

LMA Group: After selecting the appropriate LMA size for the patient, the ET Tube will be removed and the LMA will be inserted. "The LMA Insertion Time" will start with the cuff deflation of the ETT and end with successful ventilation after LMA insertion. If the LMA cannot be inserted in 3 attempts, it will be considered as a "Failed Airway" and tracheostomy will be continued with the usual method (ETT cuff will be inflated under the vocal cords).

After the ventilation is provided, arterial blood gas samples will be analyzed at the 3rd, 6th, and 10th minutes and every 5 minutes afterward until the end of the procedure. In both groups, fiberoptic bronchoscopy will assist the procedure and "Duration of the Confirmation of the Incision Site" will be noted. The bronchoscopy period will start when the physician who will perform the bronchoscope takes the bronchoscope in his hand and ends with the confirmation of the incision site. The area will be cleaned with iodide skin antiseptic, covered with a sterile cover, and surgical tools and tracheostomy kit will be prepared for the procedure. This will be recorded as "Preparation Time". Tracheostomy will preferably be performed between the 2nd and 3rd cartilage rings but one upper or lower level will be used if needed (per patients' anatomy). Local anesthesia will be applied for the incision site with 4 ml of local anesthetic solution containing %2 lidocaine and %0,00125 epinephrine. "Procedure Time" will start with skin incision and end with successful ventilation after the tracheostomy cannula cuff is inflated.

Gastric distension, hypoxia, regurgitation, hemodynamic parameters (every 3 minutes), complications, and the number of staff will be recorded. When the tracheostomy cannula is placed and the patient is ventilated, the procedure will be terminated and confirmed with an anteroposterior chest x-ray.

SPSS (Statistical Package for Social Sciences version 24) was used for statistical calculation. Parametric test results were reported as mean and standard deviation and non-parametric test results as number and percentage or median and interquartile range. The compliance of the data to normal distribution was determined by the single sample Kolmogorov-Smirnov test. Normally distributed quantitative data were compared with the independent sample T-Test, quantitative data that did not follow normal distribution were compared with the Mann-Whitney U test. A Chi-square test was used to compare qualitative data.

The significance level was determined as p \<0.05 at the 95% confidence interval for the analyzes.

02

Conditions studied

  • Intubation, Intratracheal
  • Tracheostomy
  • Laryngeal Masks
  • Intensive Care Units

Keywords

  • Percutan Dilatational Tracheostomy
  • Intensive Care Units
03

In context

Lead sponsor

Bozyaka Training and Research Hospital is the lead sponsor of 50 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 95 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Non-pregnant patients over 18 years of age
  • Patients who need a tracheostomy
  • Patients whose opening method of tracheostomy is suitable for percutaneous tracheostomy.

Exclusion criteria

Exclusion Criteria:

  • Refusal of the procedure by the patient or her legal representative
  • Patients under the age of 18
  • Body mass index> 35 patient group
  • Patients with a mass in the neck region for any reason
  • Skin infection at the procedure site
  • Coagulopathy
  • Inability to palpate the cricoid cartilage
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
52 participants (estimated)

Study arms

  • Active comparator
    ETT Group

    ETT will be repositioned with direct laryngoscopy (ETT cuff will be inflated just above the vocal cords). "The Reposition Time" will start with the cuff deflation and end with successful ventilation after repositioning. If the ETT can not be repositioned within 5 minutes, it will be considered as a "Failed Airway" and tracheostomy will be continued with the usual method (ETT cuff will be inflated under the vocal cords)

    Procedure: Endotracheal Tube Insertion · Procedure: Fiberoptic Bronchoscopy · Procedure: Radial Artery Monitoring · Diagnostic Test: Anteroposterior chest x-ray · Diagnostic Test: Arterial Blood Gas Analyses · Drug: Propofol Fresenius · Drug: Rocuronium · Drug: Fentanyl

  • Active comparator
    LMA Group

    After selecting the appropriate LMA size for the patient, the ET Tube will be removed and the LMA will be inserted. "The LMA Insertion Time" will start with the cuff deflation of the ETT and end with successful ventilation after LMA insertion. If the LMA cannot be inserted in 3 attempts, it will be considered as a "Failed Airway" and tracheostomy will be continued with the usual method (ETT cuff will be inflated under the vocal cords)

    Procedure: Laryngeal Mask Insertion · Procedure: Fiberoptic Bronchoscopy · Procedure: Radial Artery Monitoring · Diagnostic Test: Anteroposterior chest x-ray · Diagnostic Test: Arterial Blood Gas Analyses · Drug: Propofol Fresenius · Drug: Rocuronium · Drug: Fentanyl

Interventions

  • ProcedureEndotracheal Tube Insertion

    ETT will be repositioned with direct laryngoscopy (ETT cuff will be inflated just above the vocal cords)

  • ProcedureLaryngeal Mask Insertion

    After selecting the appropriate LMA size for the patient, the ET Tube will be removed and the LMA will be inserted.

  • ProcedureFiberoptic Bronchoscopy

    After the patients' airway is established, the trachea and the process area will be displayed by the physician. The success rate will be increased by performing the procedure with fiberoptic bronchoscopy.

  • ProcedureRadial Artery Monitoring

    The radial artery will be cannulated. Hemodynamic monitoring and blood gas analysis will be done in this way.

  • Diagnostic testAnteroposterior chest x-ray

    When the tracheostomy cannula is placed and the patient is ventilated, the procedure will be terminated and confirmed with anteroposterior chest x-ray.

  • Diagnostic testArterial Blood Gas Analyses

    Hypoxia, acidosis and carbon dioxide increase will be followed

  • DrugPropofol Fresenius

    2mg/kg of propofol 2% injectable solution was given and propofol infusion at the dose of 6 mg/kg/hour will be started.

  • DrugRocuronium

    0.6 mg/kg of rocuronium 50mg/5ml injectable solution was given.

    Also known as: Muscuron

  • DrugFentanyl

    1mcg/kg fentanyl of 0.5 mg/10ml injectable solution was given.

06

What researchers measure

Primary outcomes

  1. Arterial Blood Gas Analysis

    Monitoring of hypoxia, acidosis, and carbon dioxide

    Time frame: Before the procedure

  2. Arterial Blood Gas Analysis

    Monitoring of hypoxia, acidosis, and carbon dioxide

    Time frame: 3rd minute after ventilation

  3. Arterial Blood Gas Analysis

    Monitoring of hypoxia, acidosis, and carbon dioxide

    Time frame: 6th minute after ventilation

  4. Arterial Blood Gas Analysis

    Monitoring of hypoxia, acidosis, and carbon dioxide

    Time frame: 10th minute after ventilation

  5. Arterial Blood Gas Analysis

    Monitoring of hypoxia, acidosis, and carbon dioxide

    Time frame: When the tracheostomy cannula cuff is inflated

  6. Positioning time

    By placing a transverse elevation under the shoulders, the patients' neck will be extended as approprite.

    Time frame: Before the procedure

  7. The Reposition Time

    The Reposition Time will start with the cuff deflation and end with successful ventilation after repositioning. If the ETT can not be repositioned within 5 minutes, it will be considered as a "Failed Airway".

    Time frame: Before the procedure

  8. The LMA Insertion Time

    The LMA Insertion Time will start with the cuff deflation of the ETT and end with successful ventilation after LMA insertion. If the LMA cannot be inserted in 3 attempts, it will be considered as a "Failed Airway"

    Time frame: Before the procedure

  9. Duration of the Confirmation of the Incision Site

    The bronchoscopy period will start when the physician who will perform the bronchoscope takes the bronchoscope in his hand and ends with the confirmation of the incision site

    Time frame: Before the procedure

  10. Preparation Time

    Area will be cleaned with iodide skin antiseptic, covered with a sterile cover and surgical tools and tracheostomy kit will be prepared for the procedure

    Time frame: Before the procedure

  11. Procedure Time

    "Procedure Time" will start with skin incision and end with successful ventilation after tracheostomy cannula cuff is inflated.

    Time frame: 15 minutes after the procedure begins

Secondary outcomes

  1. Incidence of gastric distension

    Time frame: Throughout the tracheostomy procedure

  2. Incidence of hypoxia

    Time frame: Throughout the tracheostomy procedure

  3. Incidence of regurgitation

    Time frame: Throughout the tracheostomy procedure

  4. The number of staff needed

    Time frame: Throughout the tracheostomy procedure

  5. Heart rate

    Time frame: Every 3 minutes during the procedure

  6. Blood pressure

    Time frame: Every 3 minutes during the procedure

  7. Pulse oximeter

    Time frame: Every 3 minutes during the procedure

07

Study locations

No study locations are listed for this record.

08

References and documents

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 5, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04872881
Lead sponsor
Bozyaka Training and Research Hospital
Responsible party
Elif Göktaş (Anesthesiology Resident, Bozyaka Training and Research Hospital) — Principal investigator
First posted
May 5, 2021
Start date
May 1, 2021 (estimated)
Primary completion
Aug 1, 2021 (estimated)
Completion
Oct 1, 2021 (estimated)
Last update
May 5, 2021

Study contacts

Elif Göktaş
Contact
e.goktas44@hotmail.com
05062073485
Zeki T TEKGUL
Contact
zekittekgul@yahoo.com
05073341373
Elif Göktaş
study chair · Izmir Bozyaka Research and Trainings Hospital
Zeki T TEKGUL
study chair · Izmir Bozyaka Research and Trainings Hospital
Hüseyin ÖZKARAKAŞ
study chair · Izmir Bozyaka Research and Trainings Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion